Cargando…

Plasma Metabolomics Implicates Modified Transfer RNAs and Altered Bioenergetics in the Outcomes of Pulmonary Arterial Hypertension

BACKGROUND: Pulmonary arterial hypertension (PAH) is a heterogeneous disorder with high mortality. METHODS: We conducted a comprehensive study of plasma metabolites using ultraperformance liquid chromatography mass spectrometry to identify patients at high risk of early death, to identify patients w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rhodes, Christopher J., Ghataorhe, Pavandeep, Wharton, John, Rue-Albrecht, Kevin C., Hadinnapola, Charaka, Watson, Geoffrey, Bleda, Marta, Haimel, Matthias, Coghlan, Gerry, Corris, Paul A., Howard, Luke S., Kiely, David G., Peacock, Andrew J., Pepke-Zaba, Joanna, Toshner, Mark R., Wort, S. John, Gibbs, J. Simon R., Lawrie, Allan, Gräf, Stefan, Morrell, Nicholas W., Wilkins, Martin R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2017
Materias:	Original Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5287439/ https://www.ncbi.nlm.nih.gov/pubmed/27881557 http://dx.doi.org/10.1161/CIRCULATIONAHA.116.024602

Ejemplares similares

The resistance-compliance product of the pulmonary circulation varies in health and pulmonary vascular disease
por: Hadinnapola, Charaka, et al.
Publicado: (2015)

Plasma metabolomics exhibit response to therapy in chronic thromboembolic pulmonary hypertension
por: Swietlik, Emilia M., et al.
Publicado: (2021)

Deprivation and prognosis in patients with pulmonary arterial hypertension: missing the effect of deprivation on a rare disease?
por: Sofianopoulou, Eleni, et al.
Publicado: (2020)

Reduced plasma levels of small HDL particles transporting fibrinolytic proteins in pulmonary arterial hypertension
por: Harbaum, Lars, et al.
Publicado: (2019)

Idiopathic pulmonary arterial hypertension and co-existing lung disease: is this a new phenotype?
por: Peacock, Andrew J., et al.
Publicado: (2020)

The ADAMTS13–VWF axis is dysregulated in chronic thromboembolic pulmonary hypertension
por: Newnham, Michael, et al.
Publicado: (2019)

Chronic thromboembolic pulmonary hypertension: time for research in pathophysiology to catch up with developments in treatment
por: Toshner*, Mark, et al.
Publicado: (2014)

Plasma proteome analysis in patients with pulmonary arterial hypertension: an observational cohort study
por: Rhodes, Christopher J, et al.
Publicado: (2017)

Identification of rare sequence variation underlying heritable pulmonary arterial hypertension
por: Gräf, Stefan, et al.
Publicado: (2018)

Whole-Blood RNA Profiles Associated with Pulmonary Arterial Hypertension and Clinical Outcome
por: Rhodes, Christopher J., et al.
Publicado: (2020)

Biological heterogeneity in idiopathic pulmonary arterial hypertension identified through unsupervised transcriptomic profiling of whole blood
por: Kariotis, Sokratis, et al.
Publicado: (2021)

Author Correction: Biological heterogeneity in idiopathic pulmonary arterial hypertension identified through unsupervised transcriptomic profiling of whole blood
por: Kariotis, Sokratis, et al.
Publicado: (2022)

Autoimmunity Is a Significant Feature of Idiopathic Pulmonary Arterial Hypertension
por: Jones, Rowena J., et al.
Publicado: (2022)

Mendelian randomisation and experimental medicine approaches to interleukin-6 as a drug target in pulmonary arterial hypertension
por: Toshner, Mark, et al.
Publicado: (2022)

Metabolic pathways associated with right ventricular adaptation to pulmonary hypertension: 3D analysis of cardiac magnetic resonance imaging
por: Attard, Mark I, et al.
Publicado: (2019)

Pulmonary arterial size and response to sildenafil in chronic thromboembolic pulmonary hypertension
por: Toshner, Mark R., et al.
Publicado: (2010)

Supplementation of iron in pulmonary hypertension: Rationale and design of a phase II clinical trial in idiopathic pulmonary arterial hypertension
por: Howard, Luke S.G.E., et al.
Publicado: (2013)

Balloon pulmonary angioplasty for inoperable chronic thromboembolic pulmonary hypertension: the UK experience
por: Hoole, Stephen P, et al.
Publicado: (2020)

Log-transformation improves the prognostic value of serial NT-proBNP levels in apparently stable pulmonary arterial hypertension
por: Soon, Elaine, et al.
Publicado: (2011)

Biallelic variants of ATP13A3 cause dose-dependent childhood-onset pulmonary arterial hypertension characterised by extreme morbidity and mortality
por: Machado, Rajiv D, et al.
Publicado: (2022)

Positioning imatinib for pulmonary arterial hypertension: A phase I/II design comprising dose finding and single-arm efficacy
por: Wilkins, Martin R., et al.
Publicado: (2021)

The prognostic ability of cardiac output determined by inert gas rebreathing technique in pulmonary hypertension
por: Robertson, Lucy, et al.
Publicado: (2022)

The Role of Bioenergetics in Neurodegeneration
por: Strope, Taylor A., et al.
Publicado: (2022)

EmPHasis-10 health-related quality of life score predicts outcomes in patients with idiopathic and connective tissue disease-associated pulmonary arterial hypertension: results from a UK multicentre study
por: Lewis, Robert A., et al.
Publicado: (2021)

Predictors of outcomes in mild pulmonary hypertension according to 2022 ESC/ERS Guidelines: the EVIDENCE-PAH UK study
por: Karia, Nina, et al.
Publicado: (2023)

Acute lung injury after balloon pulmonary angioplasty results in a similar haemodynamic response and possible clinical advantage at follow‐up
por: Rodgers, Matthew S., et al.
Publicado: (2022)

Different Cytokine Patterns in BMPR2-Mutation-Positive Patients and Patients With Pulmonary Arterial Hypertension Without Mutations and Their Influence on Survival
por: Schwiening, Max, et al.
Publicado: (2022)

Balloon pulmonary angioplasty outcomes in patients previously treated by pulmonary endarterectomy surgery are inferior to those of inoperable patients
por: Kirkby, Louise C., et al.
Publicado: (2023)

Author's reply
por: Pepke-Zaba, Joanna
Publicado: (2012)

A minimal clinically important difference measured by the Cambridge Pulmonary Hypertension Outcome Review for patients with idiopathic pulmonary arterial hypertension
por: Bunclark, Katherine, et al.
Publicado: (2021)

emPHasis-10: development of a health-related quality of life measure in pulmonary hypertension
por: Yorke, Janelle, et al.
Publicado: (2014)

Expression Quantitative Trait Locus Mapping in Pulmonary Arterial Hypertension
por: Ulrich, Anna, et al.
Publicado: (2020)

Clinical trial protocol for TRANSFORM-UK: A therapeutic open-label study of tocilizumab in the treatment of pulmonary arterial hypertension
por: Hernández-Sánchez, Jules, et al.
Publicado: (2017)

A diagnostic miRNA signature for pulmonary arterial hypertension using a consensus machine learning approach
por: Errington, Niamh, et al.
Publicado: (2021)

Serum osteoprotegerin is increased and predicts survival in idiopathic pulmonary arterial hypertension
por: Condliffe, Robin, et al.
Publicado: (2012)

Lifting the fog in intermediate-risk (submassive) PE: full dose, low dose, or no thrombolysis?
por: Bhamani, Amyn, et al.
Publicado: (2019)

Genetic determinants of risk in pulmonary arterial hypertension: international genome-wide association studies and meta-analysis
por: Rhodes, Christopher J, et al.
Publicado: (2019)

Blood-Based Bioenergetic Profiling Reflects Differences in Brain Bioenergetics and Metabolism
por: Tyrrell, Daniel J., et al.
Publicado: (2017)

Supplementation with Iron in Pulmonary Arterial Hypertension. Two Randomized Crossover Trials
por: Howard, Luke S. G. E., et al.
Publicado: (2021)

Bioenergetics /
por: Lowen, Alexander
Publicado: (1975)

Cannot write session to /tmp/vufind_sessions/sess_3htkamojlisaa20d2rfcbo1q4o